Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  ArGEN-X    ARGX   NL0010832176

ARGEN-X (ARGX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

arGEN X : argenx to Present at Upcoming Investor Conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2018 | 07:01am CEST



May 17, 2018Breda,  the Netherlands / Ghent,  Belgium - argenx (Euronext  & Nasdaq: ARGX), a
clinical-stage   biotechnology   company   developing   a   deep   pipeline   of
differentiated  antibody-based therapies for the  treatment of severe autoimmune
diseases  and  cancer,  today  announced  that  Chief Executive Officer, Tim Van
Hauwermeiren, will present at several upcoming investor conferences:

  * UBS 2018 Global Healthcare Conference. Company presentation on Tuesday, May
    22, 2018 at 2:00 p.m. ET in New York City.
  * Jefferies 2018 Global Healthcare Conference. Company presentation on
    Wednesday, June 6, 2018 at 1:30 p.m. ET in New York City.
  * JMP Securities Life Sciences Conference. Panel discussion on Wednesday, June
    20, 2018 at 10:30 a.m. ET in New York City.

Live  webcasts of the UBS  and Jefferies presentations will  be available on the
Company's  website at www.argenx.com. Replays of  the webcasts will be available
for 90 days following the presentation.

About argenx
argenx  is a clinical-stage biotechnology company  developing a deep pipeline of
differentiated  antibody-based therapies for the treatment of severe auto-immune
diseases  and cancer. We  are focused on  developing product candidates with the
potential  to be  either first-in-class  against novel  targets or best-in-class
against  known,  but  complex,  targets  in  order  to  treat  diseases  with  a
significant  unmet medical need. Our ability to execute on this focus is enabled
by  our suite of differentiated  technologies. Our SIMPLE Antibody(TM) Platform,
based  on  the  powerful  llama  immune  system,  allows us to exploit novel and
complex targets, and our three antibody engineering technologies are designed to
enable us to expand the therapeutic index of our product candidates.

www.argenx.com


For further information, please contact:

Joke Comijn, Corporate Communications & IR Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com

Forward-looking Statements

The  contents of this announcement include statements that are, or may be deemed
to  be, "forward-looking  statements." These  forward-looking statements  can be
identified  by  the  use  of  forward-looking  terminology,  including the terms
"believes,"  "estimates," "anticipates," "expects," "intends," "may," "will," or
"should," and include statements argenx makes concerning the intended results of
its  strategy.  By  their  nature,  forward-looking statements involve risks and
uncertainties and readers are cautioned that any such forward-looking statements
are  not guarantees  of future  performance. argenx's  actual results may differ
materially from those predicted by the forward-looking statements as a result of
various  important factors,  including argenx's  expectations regarding  its the
inherent uncertainties associated with competitive developments, preclinical and
clinical  trial  and  product  development  activities  and  regulatory approval
requirements; argenx's reliance on collaborations with third parties; estimating
the  commercial potential  of argenx's  product candidates;  argenx's ability to
obtain and maintain protection of intellectual property for its technologies and
drugs;  argenx's  limited  operating  history;  and  argenx's  ability to obtain
additional   funding   for  operations  and  to  complete  the  development  and
commercialization  of its product candidates. A  further list and description of
these  risks,  uncertainties  and  other  risks  can  be  found in argenx's U.S.
Securities  and  Exchange  Commission  (SEC)  filings  and reports, including in
argenx's  most recent annual report  on Form 20-F filed  with the SEC as well as
subsequent  filings  and  reports  filed  by  argenx  with  the SEC. Given these
uncertainties,  the reader is  advised not to  place any undue  reliance on such
forward-looking  statements. These  forward-looking statements  speak only as of
the  date of  publication of  this document.  argenx undertakes no obligation to
publicly  update or revise the information  in this press release, including any
forward-looking statements, except as may be required by law.



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    
Source: argenx SE via GlobeNewswire

 
  

© InPublic, source European Press Releases

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ARGEN-X
09/21ARGEN X : argenx announces closing of U.S. public offering
PU
09/21ARGEN X : argenx announces closing of U.S. public offering for gross proceeds of..
GL
09/19ARGEN X : argenx announces launch of proposed public offering in the United Stat..
AQ
09/19ARGEN X : argenx reports positive topline results from Phase 2 proof-of-concept ..
AQ
09/19ARGEN X : argenx raises approximately $300.6 million in gross proceeds in a U.S...
GL
09/17ARGEN X : argenx announces launch of proposed public offering in the United Stat..
GL
09/17ARGEN X : argenx trumpets topline results from drug tests
AQ
09/17ARGEN X : argenx reports positive topline results from Phase 2 proof-of-concept ..
GL
09/10ARGEN X : argenx doses first patient in global Phase 3 registration trial of efg..
AQ
09/06ARGEN X : argenx doses first patient in global Phase 3 registration trial of efg..
PU
More news
News from SeekingAlpha
09/21YOUR DAILY SCOOP : Unum's Positive Data, Theravance's Treatment Benefit, Collect.. 
09/20Sell-siders defend Argenx after selloff; shares up 5% premarket 
09/20Premarket analyst action - healthcare 
09/19Argenx prices $300M equity offering 
09/18Argenx (ARGX) Updates Efgartigimod ITP Ph2 Topline Data - Slideshow